Inactive Instrument

Analyst Reco. Aastrom Biosciences Inc Nasdaq

Equities

US00253U4040

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Vericel Insider Sold Shares Worth $1,593,550, According to a Recent SEC Filing	Apr. 19	MT
Truist Securities Raises Vericel's Price Target to $54 From $51, Keeps Buy Rating	Mar. 01	MT
HC Wainwright Adjusts Price Target on Vericel to $53 From $46, Keeps Buy Rating	Mar. 01	MT
HC Wainwright Adjusts Price Target on Vericel to $44.50 From $41, Keeps Buy Rating	23-09-21	MT
BTIG Research Upgrades Vericel to Buy From Neutral, $39 Price Target	23-08-08	MT
HC Wainwright Adjusts Price Target on Vericel to $41 From $37, Maintains Buy Rating	23-08-03	MT
Truist Securities Adjusts Price Target on Vericel to $42 From $36, Maintains Hold Rating	23-07-19	MT
Truist Securities Adjusts Price Target on Vericel to $36 From $31, Maintains Hold Rating	23-05-11	MT
Stephens Adjusts Vericel Price Target to $42 From $39, Maintains Overweight Rating	23-05-11	MT
Truist Securities Adjusts Price Target on Vericel to $31 From $29, Maintains Hold Rating	23-02-27	MT
Truist Securities Increases Price Target on Vericel to $29 From $25, Maintains Hold Rating	23-01-31	MT
HC Wainwright Reiterates Vericel at Buy With $37 Price Target	23-01-27	MT
HC Wainwright Adjusts Price Target on Vericel to $37 From $35, Maintains Buy Rating	23-01-03	MT
Truist Securities Adjusts Price Target on Vericel to $25 From $22, Maintains Hold Rating	22-12-20	MT
HC Wainwright Slashes Price Target on Vericel to $35 from $53, Affirms Buy Rating	22-11-10	MT
BTIG Downgrades Vericel to Neutral From Buy	22-11-10	MT
Stephens Reinstates Vericel at Overweight With $40 Price Target	22-10-14	MT
BTIG Adjusts Vericel's Price Target to $34 From $45, Maintains Buy Rating	22-07-18	MT
SVB Leerink Lifts Vericel's Price Target to $45 From $40, Maintains Outperform Rating	22-02-25	MT
Truist Securities Adjusts Vericel PT to $52 From $55, Maintains Buy Rating	21-12-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aastrom Biosciences Inc Nasdaq

Equities

US00253U4040

Analyst Reco.

Filters